Identification of Two Protein-Signaling States Delineating Transcriptionally Heterogeneous Human Medulloblastoma

Cell Reports

Volumn 22, Issue 12, 2018, Pages 3206-3216

  Zomerman, Walderik W ^a   Plasschaert, Sabine L A ^a,c   Conroy, Siobhan ^a   Scherpen, Frank J ^a   Meeuwsen de Boer, Tiny G J ^a   Lourens, Harm J ^a   Guerrero Llobet, Sergi ^a   Smit, Marlinde J ^a   Slagter Menkema, Lorian ^a   Seitz, Annika ^a   Gidding, Corrie E M ^d   Hulleman, Esther ^e   Wesseling, Pieter ^c,f   Meijer, Lisethe ^b   van Kempen, Leon C ^a,g   van den Berg, Anke ^a   Warmerdam, Daniël O ^a   Kruyt, Frank A E ^a   Foijer, Floris ^a   van Vugt, Marcel A T M ^a   den Dunnen, Wilfred F A ^a   Hoving, Eelco W ^a,c   Guryev, Victor ^a   de Bont, Eveline S J M ^a   Bruggeman, Sophia W M ^a   more..

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c Department of Radiation Oncology   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e University of Amsterdam   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g MCGILL UNIVERSITY   (Canada)

Author keywords

medulloblastoma; MYC; phosphoproteome; protein synthesis; protein signaling; proteome; TP53

Indexed keywords

DNA; MYC PROTEIN; PHOSPHOPROTEIN; SONIC HEDGEHOG PROTEIN; MESSENGER RNA; MYC PROTEIN, HUMAN; PROTEIN P53; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DNA DAMAGE; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MEDULLOBLASTOMA; NEUROTRANSMISSION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; BIOSYNTHESIS; CEREBELLUM TUMOR; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

CELL LINE, TUMOR; CEREBELLAR NEOPLASMS; GENE EXPRESSION PROFILING; HEDGEHOG PROTEINS; HUMANS; MEDULLOBLASTOMA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85044111819     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2018.02.089     Document Type: Article

References (47)

1. Aebersold, R., Mann, M., Mass-spectrometric exploration of proteome structure and function. Nature 537 (2016), 347–355.
2. Akbani, R., Ng, P.K.S., Werner, H.M.J., Shahmoradgoli, M., Zhang, F., Ju, Z., Liu, W., Yang, J.-Y., Yoshihara, K., Li, J., et al. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat. Commun., 5, 2014, 3887.
3. Akita, H., Marquardt, J.U., Durkin, M.E., Kitade, M., Seo, D., Conner, E.A., Andersen, J.B., Factor, V.M., Thorgeirsson, S.S., MYC activates stem-like cell potential in hepatocarcinoma by a p53-dependent mechanism. Cancer Res. 74 (2014), 5903–5913.
4. Anagnostopoulos, A.K., Papathanassiou, C., Karamolegou, K., Anastasiadou, E., Dimas, K.S., Kontos, H., Koutsopoulos, A., Prodromou, N., Tzortzatou-Stathopoulou, F., Tsangaris, G.T., Proteomic studies of pediatric medulloblastoma tumors with 17p deletion. J. Proteome Res. 14 (2015), 1076–1088.
5. Bien-Willner, G.A., Mitra, R.D., Mutation and expression analysis in medulloblastoma yields prognostic variants and a putative mechanism of disease for i17q tumors. Acta Neuropathol. Commun., 2, 2014, 74.
6. Cavalli, F.M.G., Remke, M., Rampasek, L., Peacock, J., Shih, D.J.H., Luu, B., Garzia, L., Torchia, J., Nor, C., Morrissy, A.S., et al. Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell 31 (2017), 737–754.e6.
7. Cojoc, M., Mäbert, K., Muders, M.H., Dubrovska, A., A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. Semin. Cancer Biol. 31 (2015), 16–27.
8. Coller, H.A., Grandori, C., Tamayo, P., Colbert, T., Lander, E.S., Eisenman, R.N., Golub, T.R., Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc. Natl. Acad. Sci. USA 97 (2000), 3260–3265.
9. Conroy, S., Kruyt, F.A.E., Joseph, J.V., Balasubramaniyan, V., Bhat, K.P., Wagemakers, M., Enting, R.H., Walenkamp, A.M.E., den Dunnen, W.F.A., Subclassification of newly diagnosed glioblastomas through an immunohistochemical approach. PLoS ONE, 9, 2014, e115687.
10. Dang, C.V., MYC on the path to cancer. Cell 149 (2012), 22–35.
11. de Bono, J.S., Ashworth, A., Translating cancer research into targeted therapeutics. Nature 467 (2010), 543–549.
12. Downing, J.R., Wilson, R.K., Zhang, J., Mardis, E.R., Pui, C.-H., Ding, L., Ley, T.J., Evans, W.E., The Pediatric Cancer Genome Project. Nat. Genet. 44 (2012), 619–622.
13. Fagnocchi, L., Zippo, A., Multiple Roles of MYC in Integrating Regulatory Networks of Pluripotent Stem Cells. Front. Cell Dev. Biol., 5, 2017, 7.
14. Galardi, S., Savino, M., Scagnoli, F., Pellegatta, S., Pisati, F., Zambelli, F., Illi, B., Annibali, D., Beji, S., Orecchini, E., et al. Resetting cancer stem cell regulatory nodes upon MYC inhibition. EMBO Rep. 17 (2016), 1872–1889.
15. Hanahan, D., Rethinking the war on cancer. Lancet 383 (2014), 558–563.
16. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
17. Harris, P.S., Venkataraman, S., Alimova, I., Birks, D.K., Balakrishnan, I., Cristiano, B., Donson, A.M., Dubuc, A.M., Taylor, M.D., Foreman, N.K., et al. Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma. Mol. Cancer, 13, 2014, 72.
18. Hassan, H., Pinches, A., Picton, S.V., Phillips, R.S., Survival rates and prognostic predictors of high grade brain stem gliomas in childhood: a systematic review and meta-analysis. J. Neurooncol. 135 (2017), 13–20.
19. Hill, R.M., Kuijper, S., Lindsey, J.C., Petrie, K., Schwalbe, E.C., Barker, K., Boult, J.K.R., Williamson, D., Ahmad, Z., Hallsworth, A., et al. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer Cell 27 (2015), 72–84.
20. Jung, M., Russell, A.J., Liu, B., George, J., Liu, P.Y., Liu, T., DeFazio, A., Bowtell, D.D.L., Oberthuer, A., London, W.B., et al. A Myc activity signature predicts poor clinical outcomes in Myc-associated cancers. Cancer Res. 77 (2017), 971–981.
21. Kawauchi, D., Robinson, G., Uziel, T., Gibson, P., Rehg, J., Gao, C., Finkelstein, D., Qu, C., Pounds, S., Ellison, D.W., et al. A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell 21 (2012), 168–180.
22. Kim, J., Woo, A.J., Chu, J., Snow, J.W., Fujiwara, Y., Kim, C.G., Cantor, A.B., Orkin, S.H., A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 143 (2010), 313–324.
23. Kool, M., Koster, J., Bunt, J., Hasselt, N.E., Lakeman, A., van Sluis, P., Troost, D., Meeteren, N.S., Caron, H.N., Cloos, J., et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS ONE, 3, 2008, e3088.
24. Künkele, A., De Preter, K., Heukamp, L., Thor, T., Pajtler, K.W., Hartmann, W., Mittelbronn, M., Grotzer, M.A., Deubzer, H.E., Speleman, F., et al. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. Neuro-oncol. 14 (2012), 859–869.
25. Leon, J., Ferrandiz, N., Acosta, J.C., Delgado, M.D., Inhibition of cell differentiation: a critical mechanism for MYC-mediated carcinogenesis?. Cell Cycle 8 (2009), 1148–1157.
26. Levine, A.J., p53, the cellular gatekeeper for growth and division. Cell 88 (1997), 323–331.
27. Louis, D.N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W.K., Ohgaki, H., Wiestler, O.D., Kleihues, P., Ellison, D.W., The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 131 (2016), 803–820.
28. Morrissy, A.S., Garzia, L., Shih, D.J., Zuyderduyn, S., Huang, X., Skowron, P., Remke, M., Cavalli, F.M., Ramaswamy, V., Lindsay, P.E., et al. Divergent clonal selection dominates medulloblastoma at recurrence. Nature 529 (2016), 351–357.
29. Northcott, P.A., Jones, D.T.W., Kool, M., Robinson, G.W., Gilbertson, R.J., Cho, Y.-J., Pomeroy, S.L., Korshunov, A., Lichter, P., Taylor, M.D., Pfister, S.M., Medulloblastomics: the end of the beginning. Nat. Rev. Cancer 12 (2012), 818–834.
30. Northcott, P.A., Buchhalter, I., Morrissy, A.S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V.A., et al. The whole-genome landscape of medulloblastoma subtypes. Nature 547 (2017), 311–317.
31. Pei, Y., Moore, C.E., Wang, J., Tewari, A.K., Eroshkin, A., Cho, Y.J., Witt, H., Korshunov, A., Read, T.A., Sun, J.L., et al. An animal model of MYC-driven medulloblastoma. Cancer Cell 21 (2012), 155–167.
32. Pui, C.H., Gajjar, A.J., Kane, J.R., Qaddoumi, I.A., Pappo, A.S., Challenging issues in pediatric oncology. Nat. Rev. Clin. Oncol. 8 (2011), 540–549.
33. Ramaswamy, V., Remke, M., Bouffet, E., Faria, C.C., Perreault, S., Cho, Y.J., Shih, D.J., Luu, B., Dubuc, A.M., Northcott, P.A., et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol. 14 (2013), 1200–1207.
34. Ramaswamy, V., Remke, M., Bouffet, E., Bailey, S., Clifford, S.C., Doz, F., Kool, M., Dufour, C., Vassal, G., Milde, T., et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 131 (2016), 821–831.
35. Roussel, M.F., Robinson, G.W., Role of MYC in Medulloblastoma. Cold Spring Harb. Perspect. Med., 3, 2013, a014308.
36. Schoppy, D.W., Ragland, R.L., Gilad, O., Shastri, N., Peters, A.A., Murga, M., Fernandez-Capetillo, O., Diehl, J.A., Brown, E.J., Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J. Clin. Invest. 122 (2012), 241–252.
37. Sharma, K., D'Souza, R.C.J., Tyanova, S., Schaab, C., Wiśniewski, J.R., Cox, J., Mann, M., Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep. 8 (2014), 1583–1594.
38. Soucek, L., Whitfield, J.R., Sodir, N.M., Massó-Vallés, D., Serrano, E., Karnezis, A.N., Swigart, L.B., Evan, G.I., Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. 27 (2013), 504–513.
39. Spiegler, B.J., Bouffet, E., Greenberg, M.L., Rutka, J.T., Mabbott, D.J., Change in neurocognitive functioning after treatment with cranial radiation in childhood. J. Clin. Oncol. 22 (2004), 706–713.
40. Staal, J.A., Lau, L.S., Zhang, H., Ingram, W.J., Hallahan, A.R., Northcott, P.A., Pfister, S.M., Wechsler-Reya, R.J., Rusert, J.M., Taylor, M.D., et al. Proteomic profiling of high risk medulloblastoma reveals functional biology. Oncotarget 6 (2015), 14584–14595.
41. Taylor, M.D., Northcott, P.A., Korshunov, A., Remke, M., Cho, Y.-J., Clifford, S.C., Eberhart, C.G., Parsons, D.W., Rutkowski, S., Gajjar, A., et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 123 (2012), 465–472.
42. Truitt, M.L., Ruggero, D., New frontiers in translational control of the cancer genome. Nat. Rev. Cancer 16 (2016), 288–304.
43. Valentijn, L.J., Koster, J., Haneveld, F., Aissa, R.A., van Sluis, P., Broekmans, M.E.C., Molenaar, J.J., van Nes, J., Versteeg, R., Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc. Natl. Acad. Sci. USA 109 (2012), 19190–19195.
44. van Riggelen, J., Yetil, A., Felsher, D.W., MYC as a regulator of ribosome biogenesis and protein synthesis. Nat. Rev. Cancer 10 (2010), 301–309.
45. Wang, W.J., Wu, S.P., Liu, J.B., Shi, Y.S., Huang, X., Zhang, Q.B., Yao, K.T., MYC regulation of CHK1 and CHK2 promotes radioresistance in a stem cell-like population of nasopharyngeal carcinoma cells. Cancer Res. 73 (2013), 1219–1231.
46. Wang, X., Dubuc, A.M., Ramaswamy, V., Mack, S., Gendoo, D.M.A., Remke, M., Wu, X., Garzia, L., Luu, B., Cavalli, F., et al. Medulloblastoma subgroups remain stable across primary and metastatic compartments. Acta Neuropathol. 129 (2015), 449–457.
47. Whitfield, J.R., Beaulieu, M.-E., Soucek, L., Strategies to Inhibit Myc and Their Clinical Applicability. Front. Cell Dev. Biol., 5, 2017, 10.